Prothena Corporation plc Ordinary Shares - PRTA STOCK NEWS

Prothena Corporation reported strong financial results for Q3 and the first nine months of 2021, achieving a net income of $109.2 million for Q3 compared to a loss of $30.6 million in Q3 2020. Total revenue reached $139.2 million, including $78.5 million from Bristol Myers Squibb and $60.7 million from Novo Nordisk. The company has $601.5 million in cash and no debt. Prothena continues to advance its pipeline, including the ongoing Phase 3 trial of birtamimab and collaborations with notable partners, positioning itself for further growth.

Prothena Corporation plc (NASDAQ:PRTA) will release its third quarter and first nine months of 2021 financial results on November 4, 2021, after U.S. market close. The company, focused on novel therapies for conditions related to protein dysregulation, will not hold a conference call following the release. Prothena continues to advance its pipeline targeting diseases such as AL amyloidosis, ATTR amyloidosis, Alzheimer's, and Parkinson's. This detailed focus on neurological dysfunction and misfolded proteins positions Prothena as a key player in addressing rare and neurodegenerative diseases.

Prothena Corporation plc (NASDAQ:PRTA) announced the hiring of two new employees, granting them options to purchase a total of 140,000 ordinary shares at an exercise price of $70.74. This price reflects the closing trading price on October 1, 2021. The options will vest over four years, with 25% vesting after one year and the remaining vesting monthly over the following three years. This grant is part of Prothena's 2020 Employment Inducement Incentive Plan, approved by the board under Nasdaq guidelines.

Prothena Corporation (NASDAQ:PRTA) announced key executive changes aimed at bolstering its transition to a fully integrated biotechnology company targeting rare diseases. Tran B. Nguyen has been appointed Chief Strategy Officer while continuing his role as Chief Financial Officer. Brandon Smith steps in as Chief Operating Officer. These roles focus on enhancing Prothena's long-term growth strategy, operational capabilities, and pipeline development, aiding in its mission to commercialize novel therapeutics for conditions like AL amyloidosis and Alzheimer’s disease.

Prothena Corporation plc (NASDAQ:PRTA) announced the approval of a stock option grant to a new employee, allowing the purchase of 75,000 ordinary shares at an exercise price of $69.88. This is based on the closing trading price from September 1, 2021. The option will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. This grant aligns with Prothena's 2020 Employment Inducement Incentive Plan.

Prothena Corporation plc (NASDAQ:PRTA) announced participation in key investor conferences in September 2021, showcasing its commitment to addressing neurodegenerative diseases. Key events include Citi’s 16th Annual BioPharma Virtual Conference on September 8, featuring a fireside chat at 9:45 AM ET and a panel discussion at 11:35 AM ET. Additionally, the company will present at H.C. Wainwright's 23rd Annual Global Investment Conference on September 13 and the Cantor Global Healthcare Conference on September 27. Webcasts of these events will be available live and subsequently for 90 days on Prothena's website.

Prothena Corporation (NASDAQ:PRTA) reported a net income of $27.6 million for Q2 2021, a significant improvement from a net loss of $26.3 million in the same quarter last year. Revenue for Q2 reached $60.1 million, up from $0.2 million in Q2 2020, primarily driven by collaboration payments. The company announced multiple strategic collaborations, achieving over $200 million in milestone payments in 2021. Prothena anticipates a strong cash position of approximately $491 million by year-end, up from prior guidance of $316 million. Upcoming milestones include key clinical data presentations.

DUBLIN, Ireland, July 29, 2021 – Prothena Corporation plc (NASDAQ:PRTA) will release its second quarter and first half of 2021 financial results on August 5, 2021, after U.S. market close. The company, known for its investigational therapeutics targeting protein dysregulation associated with rare peripheral amyloid and neurodegenerative diseases, will not hold a conference call for this release. Prothena aims to advance its pipeline, which includes treatments for AL amyloidosis, ATTR amyloidosis, Alzheimer's, and Parkinson's diseases.

Prothena Corporation (NASDAQ:PRTA) presented promising data on its Alzheimer’s disease programs at the Alzheimer’s Association International Conference 2021. Highlights include the late-breaking poster on PRX012, demonstrating effective clearance of Aβ plaque in brain tissue, and a dual Aβ-tau vaccine that generates antibodies to target both amyloid and tau pathologies. PRX012 is noted for its high potency and potential for subcutaneous administration, promising improved patient compliance. The Investigational New Drug Application for PRX012 is anticipated in Q1 2022, enhancing Prothena's robust Alzheimer’s portfolio.